Two meta-analysis covering several clinical trials observed relatively poor efficacy and low response rates to PD-1/PD-L1 inhibitors vs. standard second-line chemotherapy among patients with pre-treated EGFR-mutant lung cancer (35, 36). Here, PDCD1 is linked to lung carcinoma.